Study #2024-1495
A randomized, phase 2/3, open-label study to investigate the efficacy and safety of RP2 in combination with nivolumab versus ipilimumab in combination with nivolumab in immune checkpoint inhibitor-naive adult patients with metastatic uveal melanoma
MD Anderson Study Status
Enrolling
Treatment Agent
RP2, Nivolumab, Ipilimumab
Description
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Uveal Melanoma
Study phase:
Phase II/III
Physician name:
Alexandra Ikeguchi
Department:
Melanoma Medical Oncology
For general questions about clinical trials:
1-855-807-9574
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.